Summary & Overview
HCPCS J1290: Injection, ecallantide, 1 mg
HCPCS Level II code J1290 designates a 1 mg unit of ecallantide administered by injection. Ecallantide is a targeted biologic used in acute management of certain hereditary angioedema presentations and other emergent indications where this agent is indicated; accurate coding ensures appropriate billing for high-cost specialty drugs and supports claims processing consistency across payers. Nationally, precise reporting of specialty injectables like ecallantide affects utilization tracking, prior authorization workflows, and pharmacy benefit versus medical benefit determinations.
Key payers examined include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code's clinical context and service settings, plus what to expect from payer coverage patterns and authorization requirements. The publication summarizes typical sites of service, common billing units, and implications for claims submission and reimbursement policy. It also highlights benchmarking and policy themes relevant to specialty injectable medications, including medical benefit coding practices and the role of unit-based HCPCS reporting.
Data not available in the input: associated taxonomies, specific ICD-10 diagnosis pairings, related codes, and payer-specific reimbursement rates. The content focuses on coding definition, clinical use context, and the national relevance of accurate HCPCS Level II reporting for J1290.
Billing Code Overview
HCPCS Level II code J1290 represents an injection of ecallantide, billed per 1 mg. This code is used to report administration of the ecallantide pharmaceutical product.
Service Type: Medication injection (therapeutic biologic/antibody therapy)
Typical Site of Service: Outpatient infusion or injection setting, including physician office, outpatient clinic, or hospital outpatient department.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adolescent or adult presenting to an emergency department or hospital infusion center with acute hereditary angioedema (HAE) or a severe angioedema attack characterized by progressive, nonpruritic swelling of the face, oropharynx, larynx, extremities, or abdomen. After triage and rapid airway assessment, the treating clinician (emergency physician, allergist/immunologist, or hospitalist) documents HAE or acquired C1-inhibitor deficiency as the working diagnosis and determines that targeted therapy with a plasma kallikrein inhibitor is indicated. Ecallantide (J1290) is prepared and administered by subcutaneous injection in three 10 mg doses (30 mg total) over a short interval per product labeling, with monitoring for hypersensitivity and anaphylaxis in a monitored setting for at least 60 minutes after the last dose. Typical workflow steps include: patient assessment and consent, medication order entry, pharmacy verification and preparation, subcutaneous administration by a registered nurse, observation for adverse reactions, documentation of dose and lot number, and billing of the single-strength HCPCS unit J1290 per mg administered. Common sites of service are the emergency department, observation unit, inpatient ward, or infusion clinic depending on attack severity and need for monitoring.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |